• Mashup Score: 0

    Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between ‘lowgrade’ (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to lack of adequate representation in prospective trials and large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, and two comparator groups; G3AFL (n=302) and DLBCL (n=548). Composite histology with DLBCL or low-grade FL occurred in approximately half of the G3BFL cases. With a median of 5 years follow-up, the overall survival and progression-free survival of G3BFL patients was better than that of DLBCL patients (P<0.001 and P<0.001, respectively); however, G3BFL patients were younger (P<0.001) with better performance status (P<0.001), less extranodal disease (P<0.001) and more frequently had normal lactate dehydrogenase (P<0.001) at baseline. The overall and progression-free

    Tweet Tweets with this article
    • Grade 3B follicular lymphoma: read here the results of the first large international study on prognosis, outcomes and relapse patterns of this rare #FollicularLymphoma subtype in the rituximab era. https://t.co/liQN5KBZAd https://t.co/8Cy8E3Gcku

  • Mashup Score: 2

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Tweet Tweets with this article
    • Loretta Nastoupil just gave us a brilliant interview on liso-cel for #FollicularLymphoma and the challenges of integrating CAR-T into practice! Stay tuned for this update 👉https://t.co/O9p0vDBZp4👈 @mdandersonnews @SocietyofHemOnc #SOHO23 #SOHO2023 #Lymphoma #LYMsm #HemOnc https://t.co/PaMBdtOajQ

  • Mashup Score: 0

    Katie Robinson is a medical writer based in New York. In patients with low tumor burden follicular lymphoma (FL), subcutaneous (SC) rituximab incr eased progression-free survival (PFS) and complete response (CR) rates when used in induction followed by short maintenance compared with conventional intravenous (IV) induction without maintenance, according to a study published in the Journal of Clinical Oncology. However, high rituximab exposure during the first three months of treatment initiation was the

    Tweet Tweets with this article
    • In patients with low tumor burden #follicularlymphoma, the use of subcutaneous #rituximab increased PFS and CR rates when used during induction followed by short maintenance compared with conventional IV induction without maintenance https://t.co/DaeUs4EsQ5